`571-272-7822
`
`Paper 72
`Entered: April 4, 2018
`
`
`
`
`
`
`APOTEX INC., APOTEX CORP.,
`ARGENTUM PHARMACEUTICALS LLC,
`ACTAVIS ELIZABETH LLC, TEVA PHARMACEUTICALS USA, INC.,
`SUN PHARMACEUTICAL INDUSTRIES, LTD.,
`SUN PHARMACEUTICAL INDUSTRIES, INC., and
`SUN PHARMA GLOBAL FZE,
`Petitioners,
`
`v.
`
`NOVARTIS AG.,
`Patent Owner.
`____________
`Case IPR2017-008541
`Patent US 9,187,405 B2
`_______________
`
`
`Before CHRISTOPHER M. KAISER, ROBERT A. POLLOCK, and
`KRISTI L. R. SAWERT, Administrative Patent Judges.
`
`POLLOCK, Administrative Patent Judge.
`
`
`ORDER
`Conduct of the Proceeding
`37 C.F.R. § 42.5
`
`
`
`
`
`
`
`1 Cases IPR2017-01550, IPR2017-01946, and IPR2017-01929 have been
`joined with this proceeding.
`
`
`
`IPR2017-00854
`Patent 9,187,405 B2
`
`In our Order of March 29, 2018, we permitted Petitioner to file a sur-reply
`responding to Patent Owner’s reply in support of its contingent motion to amend.
`Paper 66, 3. By email dated April 4, 2018, Patent Owner seeks clarification
`regarding the scope of argument and supporting testimony permitted in the
`authorized sur-reply. See Ex. 1013.
`Our Guidance with respect to Patent Owner replies to Petitioners’
`oppositions to motions to amend applies equally with respect to Petitioner’s sur-
`reply here:
`A reply may only respond to arguments raised in the corresponding
`opposition. § 42.23. While replies can help crystalize issues for
`decision, a reply that raises a new issue or belatedly presents evidence
`will not be considered and may be returned. The Board will not attempt
`to sort proper from improper portions of the reply. Examples of
`indications that a new issue has been raised in a reply include new
`evidence necessary to make out a prima facie case for the patentability
`or unpatentability of an original or proposed substitute claim, and new
`evidence that could have been presented in a prior filing.
`Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,767 (Aug. 14, 2012).
`Accordingly, Petitioner’s sur-reply and any supporting expert testimony shall be
`limited to responding to arguments and citations to expert testimony expressly set
`forth in Patent Owner’s Reply to Petitioner’s Opposition to Patent Owner’s
`contingent motion to amend.
`
`
`SO ORDERED
`
` 2
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-00854
`Patent 9,187,405 B2
`FOR PETITIONER APOTEX:
`
`Steven W. Parmelee
`Michael T. Rosato
`Jad A. Mills
`WILSON SONSINI GOODRICH & ROSATI
`sparmelee@wsgr.com
`mrosato@wsgr.com
`jmills@wsgr.com
`
`FOR PETITIONER ARGENTUM:
`
`Teresa Stanek Rea
`Deborah H. Yellin
`Shannon M. Lentz
`CROWELL & MORING LLP
`trea@crowell.com
`dyellin@crowell.com
`slentz@crowell.com
`
`Tyler C. Liu
`ARGENTUM PHARMACEUTICALS, LLC
`tliu@agpharm.com
`
`FOR PETITIONER TEVA:
`
`Amanda Hollis
`Eugene Goryunov
`KIRKLAND & ELLIS LLP
`Amanda.hollis@kirkland.com
`egoryunov@kirkland.com
`
`FOR PETITIONER SUN PHARMA:
`
`Samuel Park
`WINSTON & STRAWN LLP
`
` 3
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2017-00854
`Patent 9,187,405 B2
`FOR PATENT OWNER:
`Jane M. Love
`GIBSON, DUNN & CRUTCHER LLP
`jlove@gibsondunn.com
`
`
`
`
`
` 4
`
`
`
`
`
`